Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY (LLY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Eli Lilly & Co. : Lilly to Discontinue Late-Stage Tabalumab RA Program on Lack of Efficacy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/07/2013 | 07:59pm CEST

--Lilly to discontinue rheumatoid arthritis Phase 3 program for tabalumab

--Company will take a first-quarter charge of about $50 million

--Tabalumab continues to be in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

(Updates with additional details, share movement)

 
   By Saabira Chaudhuri 
 

Eli Lilly & Co. (LLY) said it will discontinue the rheumatoid arthritis Phase 3 program for its drug, tabalumab, citing a lack of efficacy.

The announcement comes less than two months after the drug company said it would stop one of three late-stage registration studies of tabalumab due to insufficient efficacy. At the time, Lilly said it was continuing to evaluate tabalumab in two other Phase 3 rheumatoid-arthritis registration studies as well as an open-label extension study and several smaller studies.

Lilly on Thursday said it has decided to discontinue the development of tabalumab in its current rheumatoid-arthritis program based on the outcomes of two separate interim-futility analyses. All ongoing Phase 2 and Phase 3 rheumatoid-arthritis studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Dr. Eiry Roberts, vice president of autoimmune product development at Lilly.

The decision is expected to result in a first-quarter charge to research-and-development expenses of about $50 million.

A spokesperson for the company noted Tabalumab is still in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

The Indianapolis company is experiencing one of the steepest patent cliffs in the drug industry, grappling with recent and looming generic competition for top-selling drugs as a result of patent expirations. The company lost exclusivity for its former No. 1 product, Zyprexa, in October 2011, and it will lose U.S. patent protection for the blockbuster antidepressant Cymbalta this December.

Lilly is trying to replenish revenue lost to generic competition for the older drugs by bringing new products to market and by increasing sales of drugs that remain patent-protected.

Last month, Lilly said its fourth-quarter earnings slipped 3.6% as the drug maker recorded weaker revenue as sales of Zyprexa slid.

Shares of Lilly, which backed its view for the year, edged down 41 cents to $53.52 in recent trading. The stock has risen 36% in the past 12 months.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
05/17ELI LILLY AND : Data on Immunoglobulins Described by Researchers at Eli Lilly an..
AQ
05/17ELI LILLY AND : Trademark Application for "GO DOSE" Filed by Eli Lilly
AQ
05/17ELI LILLY AND : Trademark Application for "DOSE CONDUCTOR" Filed
AQ
05/17ELI LILLY AND : An Application for the Trademark "YELARIAT" Has Been Filed by El..
AQ
05/17ELI LILLY AND : Findings on Powder Technology Reported by Investigators at Eli L..
AQ
05/17ELI LILLY AND : Lilly Announces Agreement To Acquire ARMO BioSciences
AQ
05/16Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 billion
RE
05/16ELI LILLY AND COMPANY : Ex-dividend day for
FA
05/15ELI LILLY AND : Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Eva..
PR
05/14WEISSLAW LLP : ARMO BioSciences Inc. Acquisition May Not Be In The Best Interest..
PR
More news
News from SeekingAlpha
05/19Spotlight On Gambling Reset And Banking Bill 
05/18J&J bails on Alzheimer's candidate atabecestat on toxicity issues 
05/18Amgen's first mover advantage with Aimovig bodes well - analysts 
05/18Investors bullish on biotechs after Trump drug pricing speech 
05/18How To Retire Today With $1 Million 
Financials ($)
Sales 2018 23 982 M
EBIT 2018 6 360 M
Net income 2018 4 419 M
Debt 2018 3 797 M
Yield 2018 2,85%
P/E ratio 2018 19,22
P/E ratio 2019 16,14
EV / Sales 2018 3,85x
EV / Sales 2019 3,71x
Capitalization 88 636 M
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 90,9 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Jan M. Lundberg Executive Vice President-Science & Technology
Michael R. Meadows VP & Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY-3.32%88 636
JOHNSON & JOHNSON-11.36%332 184
PFIZER-1.41%212 424
NOVARTIS-6.55%202 969
ROCHE HOLDING LTD.-8.90%193 622
MERCK AND COMPANY5.10%158 916